Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AFMap-UNet enables accurate nuclear segmentation of atomic force microscopy images with minimal training data.

Scientific reports·2026
Same author

The global landscape of SCD and approach to case work-up in Latin America: a LAHRS and SOBRAC survey.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Functional validation of a modified platelet desialylation test for immune and hereditary thrombocytopenias.

Transfusion medicine (Oxford, England)·2026
Same author

Ancestry-informative regulatory variants at KCNB1 modulate adipogenesis and body mass index.

Frontiers in endocrinology·2026
Same author

Danon Disease: Understanding the Role of LAMP2 Variants in Cardiomyopathy and Multisystemic Involvement.

Arquivos brasileiros de cardiologia·2026
Same author

A deep learning ECG model for identification and localization of occlusion myocardial infarction.

Nature communications·2026

Related Experiment Video

Updated: May 17, 2026

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

Non-HFE hemochromatosis.

Paulo Caleb Júnior de Lima Santos1, Carla Luana Dinardo, Rodolfo Delfini Cançado

  • 1Faculdade de Medicina da Universidade de São Paulo - USP, São Paulo, SP, Brazil.

Revista Brasileira De Hematologia E Hemoterapia
|October 11, 2012
PubMed
Summary

Hereditary hemochromatosis (HH) involves HFE mutations in 80% of cases. This review focuses on the remaining 20%, known as non-HFE hemochromatosis, exploring its genetic causes, clinical features, and management strategies.

Keywords:
HemochromatosisIron metabolism disordersIron overload

More Related Videos

Measurement of Heme Synthesis Levels in Mammalian Cells
09:43

Measurement of Heme Synthesis Levels in Mammalian Cells

Published on: July 9, 2015

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Related Experiment Videos

Last Updated: May 17, 2026

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

Measurement of Heme Synthesis Levels in Mammalian Cells
09:43

Measurement of Heme Synthesis Levels in Mammalian Cells

Published on: July 9, 2015

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Area of Science:

  • Genetics and Molecular Biology
  • Hematology
  • Internal Medicine

Background:

  • Hereditary hemochromatosis (HH) is an autosomal recessive disorder.
  • HFE gene mutations account for approximately 80% of HH cases.
  • Non-HFE hemochromatosis comprises the remaining 20% of HH cases.

Purpose of the Study:

  • To review the molecular, clinical, and management aspects of non-HFE hemochromatosis.
  • To elucidate the genetic underpinnings of non-HFE hemochromatosis.
  • To provide a comprehensive overview of rare forms of HH.

Main Methods:

  • Literature review of genetic databases and clinical studies.
  • Analysis of molecular mechanisms of iron overload in non-HFE HH.
  • Synthesis of clinical presentations and diagnostic criteria.
  • Evaluation of current and emerging treatment strategies.

Main Results:

  • Four main genes (HJV, HAMP, TFR2, SLC40A1) are implicated in non-HFE hemochromatosis.
  • Non-HFE HH presents with diverse clinical phenotypes and varying severity.
  • Genetic mutations in HJV (type 2A), HAMP (type 2B), TFR2 (type 3), and SLC40A1 (type 4) define distinct subtypes.
  • Early diagnosis and management are crucial for preventing complications.

Conclusions:

  • Non-HFE hemochromatosis represents a heterogeneous group of disorders.
  • Understanding the specific genetic mutations is key for accurate diagnosis and tailored treatment.
  • Further research is needed to optimize management protocols for non-HFE HH subtypes.